Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Luca Inverardi
Ophysio, Inc., Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ophysio, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Inverardi holds (b)(4) equity in Ophysio. Ophysio is a start-up company whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Dr. Inverardi is an inventor of intellectual property (IP) used in the PHS-funded research. The IP is licensed to Ophysio, in which Dr. Inverardi has the aforementioned financial interest.
technologyIn vitro maturation of BMP-7-responsive pancraeatic beta cell progenitors by oxygen modulation
NARRATIVE Progress in the efficient generation of insulin-producing cells is expected to result in new cell therapies for type 1 and 2 diabetes (T1/2D). Ophysio, Inc. has successfully developed a platform to aid in the differentiation of such cells from different sources. Our patented technology is based on the accurate provision of physiological oxygenation, which conventional means of culture cannot achieve. Here we seek to expand the application of this principle to the maturation of a novel sub-population of pancreatic progenitor cells that our collaborators at the University of Miami have described in human non-endocrine pancreatic tissue (hNEPT), which comprises 98% of the pancreas and is routinely discarded after the insulin-producing islets (used for islet transplantation) are isolated. These progenitors are characterized by their responsiveness to BMP-7, an FDA-approved agent. Coupled with Ophysio?s technology for enhanced maturation, this approach has rapid translational potential for the effective treatment of T1/2D, and as such is highly aligned with the NIH mission.
Filed on November 22, 2016.
Tell us what you know about Luca Inverardi's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Luca Inverardi”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Luca Inverardi | Ophysio, Inc. | Conflict of Interest | Ophysio, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.